Jax DiEugenio

FDA Grants Fast Track Designation to BI-1808 in Select Cutaneous T-Cell Lymphoma

May 3rd 2025

BI-1808 has received FDA fast track designation for the treatment of patients with select cutaneous T-cell lymphoma subtypes.

Dr Hall on the Feasibility of ICI Continuation and Rechallenge Strategies in Second-Line Metastatic RCC

May 2nd 2025

Evan T. Hall, MD, MPhil, discusses the evolving evidence base surrounding ICI continuation and rechallenge strategies in the second-line treatment of metastatic renal cell carcinoma.

Dr Shreenivas on the FDA Approval of Penpulimab Plus Chemo for Frontline Non-Keratinizing Nasopharyngeal Carcinoma

May 2nd 2025

Aditya Shreenivas, MD, MS, discusses the FDA approval of penpulimab plus chemotherapy for the frontline treatment of non-keratinizing nasopharyngeal carcinoma.

Oncology Experts Highlight Top Takeaways From the 2025 AACR Annual Meeting

May 2nd 2025

Experts from across oncology specialties shared some of the most talked-about abstracts and discussions from the 2025 AACR Annual Meeting.

FDA Issues CRL to TLX101-CDx for Glioma Imaging

May 1st 2025

The FDA issued a complete response letter to the new drug application seeking the approval of TLX101-CDx as an imaging agent for glioma.

KN026 Plus Chemo Improves PFS in Pretreated HER2+ Gastric/GEJ Cancer

May 1st 2025

KN026 plus chemotherapy significantly improves PFS in second-line and later HER2-positive advanced gastric/GEJ cancer.

Dr Kuerer on Selective Surgery Omission After Response to Neoadjuvant Therapy in Invasive Breast Cancer

April 30th 2025

Henry M. Kuerer, MD, PhD, FACS, CMQ, discusses a study on selective elimination of breast surgery after exceptional response to neoadjuvant therapy in early breast cancer.

Dr Randall on the Use of Osteosarcoma Spheroid Models to Streamline Preclinical Therapeutic Development

April 30th 2025

R. Lor Randall, MD, FASCO, discussed the development and application of three-dimensional spheroid models for high-throughput drug screening in osteosarcoma research.

Dr Shadman on the Utility of a Meta Analysis of BTK Inhibitors in R/R CLL

April 30th 2025

Mazyar Shadman, MD, MPH, discusses the rationale and methodological framework of a network meta analysis of BTK inhibitors in relapsed/refractory CLL.

Adjuvant Trifluridine/Tipiracil Benefit is Limited to Select Subgroups in MRD+ CRC

April 30th 2025

Trifluridine/tipiracil showed a favorable safety profile and numerically improved DFS vs placebo in MRD-positive CRC.

Dr Petrylak on the Importance of Early Detection to Minimize Treatment Intensity in Testicular Cancer

April 30th 2025

Neoadjuvant Botensilimab Plus Balstilimab Is Active, Safe Regardless of Mismatch Repair Status in Solid Tumors

April 30th 2025

Botensilimab and balstilimab proved active and safe as neoadjuvant therapy in patients with mismatch repair–deficient and –proficient solid tumors.

CHMP Recommends Approval of At-Home, Subcutaneous Trastuzumab/Pertuzumab in HER2+ Breast Cancer

April 30th 2025

The EMA’s CHMP has recommended at-home administration of pertuzumab, trastuzumab and hyaluronidase combination therapy for HER2+ breast cancer.

FDA Grants Fast Track Designation to INX-315 in CCNE1-Amplified, Platinum-Resistant Ovarian Cancer

April 30th 2025

INX-315 has received FDA fast track designation for the treatment of patients with CCNE1-amplified, platinum-resistant or refractory ovarian cancer.

Testicular Cancer Awareness Month: Early Detection and Risk Assessment Pave the Way Toward Optimal Outcomes

April 30th 2025

Adam Calaway, MD, MPH, highlights the need for early detection and education in testicular cancer.

Avutometinib/Abemaciclib/Fulvestrant Combo Is Active, Safe in CDK4/6 Inhibitor–Resistant HR+/HER2– Metastatic Breast Cancer

April 29th 2025

Avutometinib plus abemaciclib and fulvestrant had manageable toxicity in CDK4/6-resistant, HR+/HER2– metastatic breast cancer.

Dr Scilipoti on the Value of Life Expectancy Assessments to Guide Prostate Cancer Treatment Strategies

April 29th 2025

Pietro Scilipoti, MD, discusses the need for better life expectancy assessment to guide prostate cancer treatment strategies.

Dr Guerrero-Ramos on the Potential Role of TAR-200 in BCG-Unresponsive Papillary NMIBC

April 29th 2025

Felix Guerrero-Ramos, MD, PhD, discusses the potential role of TAR-200 in high-risk, BCG-unresponsive, papillary-only non–muscle-invasive bladder cancer.

Disease Features and Treatment Intolerance Inform Pirtobrutinib Use in Pretreated CLL: With Nicole Lamanna, MD

April 28th 2025

Dr Lamanna discusses how disease progression, treatment intolerance, and prior therapy exposure inform the decision to initiate pirtobrutinib in CLL.

Bria-IMT Plus Checkpoint Inhibition Is Safe and Yields Clinical Benefit in Pretreated Metastatic Breast Cancer

April 28th 2025

Bria-IMT plus checkpoint inhibition showed a manageable safety profile and activity in metastatic breast cancer.